Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

NCT06827080 is registered in ClinicalTrials.gov with Zhengguo Chen as lead sponsor.

NCT NCT06827080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06827080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Zhengguo Chen
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
February 11, 2025
Completion date
December 1, 2026
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, metastatic castration-resistant prostate cancer, mcrpc